<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/425C1994-4AF3-4F87-AA91-B980EF37664C"><gtr:id>425C1994-4AF3-4F87-AA91-B980EF37664C</gtr:id><gtr:name>University at Buffalo</gtr:name><gtr:address><gtr:line1>12 Capen Hall</gtr:line1><gtr:postCode>14260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/425C1994-4AF3-4F87-AA91-B980EF37664C"><gtr:id>425C1994-4AF3-4F87-AA91-B980EF37664C</gtr:id><gtr:name>University at Buffalo</gtr:name><gtr:address><gtr:line1>12 Capen Hall</gtr:line1><gtr:postCode>14260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB4660FA-B951-42E5-A0AE-F9093BB40CE4"><gtr:id>FB4660FA-B951-42E5-A0AE-F9093BB40CE4</gtr:id><gtr:firstName>Kristien</gtr:firstName><gtr:surname>Boelaert</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DB736AFF-072B-4899-B0CD-BCB2B3AA8BBA"><gtr:id>DB736AFF-072B-4899-B0CD-BCB2B3AA8BBA</gtr:id><gtr:firstName>Jayne</gtr:firstName><gtr:surname>Franklyn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D67F26B-2338-4965-90ED-F51E5C2A0F0A"><gtr:id>2D67F26B-2338-4965-90ED-F51E5C2A0F0A</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McCabe</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700064"><gtr:id>9105962A-E0F7-481F-9BD4-A4F3D8F9B348</gtr:id><gtr:title>New mechanisms of sodium iodide Symporter Repression</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700064</gtr:grantReference><gtr:abstractText>Thyroid cancer is relatively common, and growing in incidence. A main treatment option for thyroid cancer is radioactive iodide, which is concentrated in the thyroid, and then kills cancer cells. One problem with this is that the protein NIS which helps thyroid cells take up the radioactive iodide is not as active in cancer cells as it is in normal cells. This means that the treatment is not as effective as it could be. We are aiming to change this. 

We have discovered that two genes called PTTG and PBF reduce the ability of the NIS to function. We therefore want to explore how we can overcome this effect, particularly because thyroid and other cancers have high levels of PTTG and PBF. If we can prevent PTTG and PBF from stopping NIS uptaking radioactive iodide, this should improve therapy and mean that this treatment might also work better in other cancers in which radioactive iodide is being tested.</gtr:abstractText><gtr:technicalSummary>The sodium iodide symporter (NIS) offers the unique potential of being both a diagnostic and a therapeutic gene: It is possible to image, monitor and treat tumours by exploiting NIS mediated uptake of radioiodide. Advances in understanding the factors which regulate the NIS gene have profound implications for the treatment of thyroid tumours, as well as breast cancer and other non-thyroidal tumours currently being assessed for NIS-mediated therapy. We have recently discovered that pituitary tumor transforming gene (PTTG) and its binding factor (PBF) inhibit NIS activity in vitro, and have mapped the promoter elements responsible. PTTG and PBF are over-expressed in thyroid and other tumours, and high expression of both genes in thyroid cancer is associated with aggressive tumour behaviour. We now intend to explore this novel link between two proto-oncogenes and a critical symporter protein through a variety of approaches. 

Our central model will be human primary thyroid cells, which actively uptake iodide, are easily transfectable and express relatively low endogenous levels of PTTG and PBF. We will seek to understand the exact mechanisms of repression, to investigate ways of overcoming this repression and to extrapolate our findings to non-thyroidal cells. Our hypothesis is that amelioration of PTTG and PBF repression of NIS activity in patients with high expression of these two oncogenes will increase the efficacy of radioiodide treatment, both in thyroid tumours and in non-thyroidal cancers where NIS may be used for ablative therapy.</gtr:technicalSummary><gtr:fund><gtr:end>2011-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>313604</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University at Buffalo</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Roswell Park Cancer Institute</gtr:department><gtr:description>Dr Moray campbell</gtr:description><gtr:id>1DA8DE8E-39A1-4705-9F9C-B2B28D102E11</gtr:id><gtr:impact>Two papers, one currently under revision at Carcinogenesis and under review.</gtr:impact><gtr:outcomeId>5CDB1AA4995-1</gtr:outcomeId><gtr:partnerContribution>Two papers under revision and under review.</gtr:partnerContribution><gtr:piContribution>Numerous telephhone meetings and exchange of data and ideas.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>197256</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D7C83BF8-8450-4E6A-A3B6-BC48DABEE842</gtr:id><gtr:outcomeId>p5aMxQxLnW60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A thyroid transgenic mouse line over-expressing the gene PBF.</gtr:description><gtr:id>3741A5A8-CD1B-46AF-826E-01D89ED3FDF4</gtr:id><gtr:impact>We now understand the physiology of how PBF induces goitrogenesis.</gtr:impact><gtr:outcomeId>3910D9B6BC2</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PBF-Tg mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2092C1E6-0E51-4469-9C46-812D58474D1D</gtr:id><gtr:title>A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/144fa3a7f348029948cb76b50c19ba1c"><gtr:id>144fa3a7f348029948cb76b50c19ba1c</gtr:id><gtr:otherNames>Smith VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>34FC5051A43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AF81682-9AD3-475F-8D0B-1D97410D7857</gtr:id><gtr:title>Thyroid cancer: finding the malignant thyroid nodule in the haystack.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f89114f898cbfd5118985408745c4f33"><gtr:id>f89114f898cbfd5118985408745c4f33</gtr:id><gtr:otherNames>Boelaert K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn><gtr:outcomeId>pm_14033_23_21878895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D0D6ADF-0EA8-46BD-A27E-610FF074C6CC</gtr:id><gtr:title>PTTG-binding factor (PBF) is a novel regulator of the thyroid hormone transporter MCT8.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/144fa3a7f348029948cb76b50c19ba1c"><gtr:id>144fa3a7f348029948cb76b50c19ba1c</gtr:id><gtr:otherNames>Smith VE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>pm_14033_23_22535767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22F06A1F-53C7-4329-A99E-5BDB81F898B4</gtr:id><gtr:title>Pituitary tumor transforming gene binding factor: a new gene in breast cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d058ad0575b15ba2c32871d75af1652"><gtr:id>2d058ad0575b15ba2c32871d75af1652</gtr:id><gtr:otherNames>Watkins RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>SAQF9Bch5a8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C23B8AA-1204-4E2B-A2E6-4995397ACABC</gtr:id><gtr:title>Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/012898a7c14605d6a0c62c3803d6c2c7"><gtr:id>012898a7c14605d6a0c62c3803d6c2c7</gtr:id><gtr:otherNames>Read ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>FwGoigSRrJi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B137BA4D-A33B-430B-A742-BAE58F308685</gtr:id><gtr:title>Mining the proteome: the application of tandem mass spectrometry to endocrine cancer research.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc2a5ec38a278217b3bed88e037a7848"><gtr:id>fc2a5ec38a278217b3bed88e037a7848</gtr:id><gtr:otherNames>Sharma N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn><gtr:outcomeId>pm_14033_23_22555494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9269BA98-57DF-4BE5-800C-92CCA66727EB</gtr:id><gtr:title>Adenovirus E4orf3 targets transcriptional intermediary factor 1? for proteasome-dependent degradation during infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b803930f2e8e8cc201d1ce0a0373503"><gtr:id>6b803930f2e8e8cc201d1ce0a0373503</gtr:id><gtr:otherNames>Forrester NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14033_23_22205733</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700064</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>